Prospective Observational Study of COVID-19 Vaccination in Patients with Thoracic Malignancies: Adverse Events, Breakthrough Infections and Survival Outcomes.

Prospective Observational Study of COVID-19 Vaccination in Patients with Thoracic Malignancies: Adverse Events, Breakthrough Infections and Survival Outcomes.

Publication date: Feb 27, 2024

Due to the devastating COVID-19 pandemic, a preventive tool in the form of vaccination was introduced. Thoracic cancer patients had one of the highest rates of morbidity and mortality due to COVID-19 disease, but the lack of data about the safety and effectiveness of vaccines in this population triggered studies like ours to explore these parameters in a cancer population. Out of 98 patients with thoracic malignancies vaccinated per protocol, 60-75% experienced some adverse events (AE) after their first or second vaccination, most of them were mild and did not interfere with their daily activities. Out of 17 severe AEs reported, all but one were resolved shortly after vaccination. No significant differences were noted considering AE occurrence between different cancer therapies received after the first or second vaccination dose, p = 0. 767 and p = 0. 441, respectively. There were 37 breakthrough infections either after the first (1), second (13) or third (23) vaccine dose. One patient died as a direct consequence of COVID-19 infection and respiratory failure, and another after disease progression with simultaneous severe infection. Eight patients had moderate disease courses, received antiviral therapies and survived without consequences. Vaccination did not affect the time to disease progression or death from underlying cancer.

Open Access PDF

Concepts Keywords
Cancer adverse events
Daily breakthrough infection
Morbidity cancer therapy
Thoracic COVID-19 vaccination
Vaccination thoracic malignancies

Semantics

Type Source Name
disease MESH COVID-19
disease VO vaccination
disease MESH Malignancies
disease MESH Breakthrough Infections
disease VO thoracic cancer
disease MESH morbidity
disease VO LACK
disease VO effectiveness
disease VO population
disease VO vaccinated
disease VO protocol
disease VO vaccination dose
disease VO vaccine dose
disease MESH infection
disease MESH respiratory failure
disease MESH disease progression
disease VO time
disease MESH death
drug DRUGBANK Coenzyme M
disease MESH emergency
drug DRUGBANK Nonoxynol-9
disease MESH complications
disease VO effective
disease VO vaccine
disease IDO production
drug DRUGBANK Trestolone
disease MESH seroconversion
disease VO primary vaccination
disease VO dose
disease MESH lung cancer
disease MESH malignant mesothelioma
disease VO USA
disease VO manufacturing
disease IDO blood
disease VO injection
disease IDO site
disease MESH arthralgia
disease MESH upper respiratory tract infection
disease MESH pneumonia
disease MESH acute respiratory distress syndrome
disease MESH shock
disease VO organ
drug DRUGBANK Medical air
disease VO adverse event
disease MESH musculoskeletal pain
disease VO frequency
disease MESH pericarditis
disease MESH myocarditis
drug DRUGBANK Fenamole
disease MESH causality
drug DRUGBANK Oxygen
drug DRUGBANK Dexamethasone
drug DRUGBANK Methylprednisolone
disease MESH hematological malignancies
disease MESH COPD
disease MESH allergic reaction
disease MESH syndrome
disease MESH hepatitis
disease MESH cardiac tamponade
drug DRUGBANK Dopamine
drug DRUGBANK Levosimendan
drug DRUGBANK Heparin
disease VO unvaccinated
drug DRUGBANK Aspartame
drug DRUGBANK Tropicamide
disease VO organization
disease IDO entity
drug DRUGBANK Etoperidone
disease VO Ad26.COV2.S
drug DRUGBANK Vinblastine
drug DRUGBANK Efavirenz
disease MESH Thrombosis
disease MESH Thrombocytopenia
disease VO vaccine effectiveness
disease MESH Coronavirus Infection
drug DRUGBANK Flurbiprofen
drug DRUGBANK Pembrolizumab
disease MESH Small Cell Lung Cancer
pathway KEGG Small cell lung cancer

Original Article

(Visited 1 times, 1 visits today)